ICON will use Intel Pharma Analytics Platform in clinical trials

| By | AI, Clinical Trials, Drug Development
0
403

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, agreed on preliminary deal terms with Intel Corporation to enable ICON to offer the Intel Pharma Analytics Platform for use in clinical trials.

The Intel platform is an edge-to-cloud artificial intelligence (AI) solution that enables remote monitoring and continuous capture of clinical data from study subjects using sensors and wearable devices, and can apply machine learning techniques to objectively measure symptoms and quantify the impact of therapies.

The Intel Pharma Analytics Platform provides benefits for pharmaceutical companies seeking to speed and simplify clinical trials, reduce trial costs, and gather more objective evidence; by transitioning to automatic collection of consistent, unbiased data, remote monitoring for data analysis, and delivering improved patient experience. These changes will help accelerate time-to-market for new drugs, by producing high-quality data and increasing patient retention, leading to shorter trials.

ICON specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries.

SOURCE: icon
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.